Skip to main content
SpringerLink
Log in

Antiplatelet and Anticoagulant Agents

  • Chapter
  • First Online:
Management of Bleeding Patients

  • 1017 Accesses

Abstract

Numerous antithrombotic agents have been developed and approved for use in patients at risk for recurrent venous and arterial thromboembolism. Currently, the treatment options for anticoagulation extend beyond the conventional vitamin K antagonists and antiplatelet agents and now increasingly include direct oral anticoagulants (DOACs). While DOACs provide increased convenience to the patient, they present unique challenges in the management of patients who experience bleeding or those who require urgent surgery. This chapter examines the strategies available for reversal and perioperative management of patients on various antithrombotic agents and discusses the limitations and controversies associated with the available reversal strategies.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 119.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 159.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Similar content being viewed by others

References

  1. Beauregard KM, Carper K. Outpatient prescription anticoagulants utilization and expenditures for the U.S. Civilian noninstitutionalized population age 18 and older. Statistical Brief #268. Rockville, MD: Agency for Healthcare Research and Quality; 2007 (Government agency report).

    Google Scholar 

  2. Eickelboom JW, et al. Rivaroxaban with or without aspirin in stable cardiovascular disease. N Engl J Med. 2017;377:1319–30.

    Article  Google Scholar 

  3. Douketis JD, Spyropoulos AC, Kaatz S, Becker RC, Caprini JA, Dunn AS, Garcia DA, Jacobson A, Jaffer AK, Kong DF, Schulman S, Turpie AG, Hasselblad V, Ortel TL, BRIDGE Investigators. Perioperative bridging anticoagulation in patients with atrial fibrillation. N Engl J Med. 2015;373:823–33.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Matsumoto M, Mabe K, Tsuda M, Ono M, Omori S, Takahashi M, Yoshida T, Ono S, Nakagawa M, Nakagawa S, Shimizu Y, Kudo T, Sakamoto N, Kato M. Multicenter study on hemorrhagic risk of heparin bridging therapy for periendoscopic thromboprophylaxis. BMC Gastroenterol. 2015;15:89.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  5. Palmerini, et al. 3, 6 or 12 months of DAPT after DES with or without ACS. Eur Heart J. 2017;38:1034–43.

    CAS  PubMed  PubMed Central  Google Scholar 

  6. Wysokinski WE, McBane RD, Daniels PR, et al. Periprocedural anticoagulation management of patients with nonvalvular atrial fibrillation. Mayo Clin Proc. 2008;83(6):639–45.

    Article  CAS  PubMed  Google Scholar 

  7. Spyropoulos AC, Douketis JD. How I treat anticoagulated patients undergoing an elective procedure or surgery. Blood. 2012;120(15):2954–62.

    Article  CAS  PubMed  Google Scholar 

  8. Garcia DA, Regan S, Henault LE, et al. Risk of thromboembolism with short-term interruption of warfarin therapy. Arch Intern Med. 2008;168(1):63–9.

    Article  CAS  PubMed  Google Scholar 

  9. Kaatz S, Douketis JD, White RH, Zhou H. Can the CHADS2 score predict postoperative stroke risk in patients with chronic atrial fibrillation who are having elective non-cardiac surgery? J Thromb Haemost. 2011;9:P-WE-367.

    Google Scholar 

  10. Kaatz S, Douketis JD, Zhou H, Gage BF, White RH. Risk of stroke after surgery in patients with and without chronic atrial fibrillation. J Thromb Haemost. 2010;8(5):884–90.

    CAS  PubMed  Google Scholar 

  11. Shoeb M, Fang MC. Assessing bleeding risk in patients taking anticoagulants. J Thromb Thrombolysis. 2013;35:312–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Tafur AJ, McBane IIR, Wysokinski WE, et al. Predictors of major bleeding in peri-procedural anticoagulation management. J Thromb Haemost. 2012;10(2):261–7.

    Article  CAS  PubMed  Google Scholar 

  13. Carrier M, Le Gal G, Wells PS, Rodger MA. Systematic review: case-fatality rates of recurrent venous thromboembolism and major bleeding events among patients treated for venous thromboembolism. Ann Intern Med. 2010;152(9):578–89.

    Article  PubMed  Google Scholar 

  14. Douketis JD, Gu CS, Schulman S, Ghirarduzzi A, Pengo V, Prandoni P. The risk for fatal pulmonary embolism after discontinuing anticoagulant therapy for venous thromboembolism. Ann Intern Med. 2007;147(11):766–74.

    Article  PubMed  Google Scholar 

  15. Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA. 2001;285(22):2864–70.

    Article  CAS  PubMed  Google Scholar 

  16. Biancari F, Asim Mahar MA, Kangasniemi OP. CHADS2 and CHA2DS2-VASc scores for prediction of immediate and late stroke after coronary artery bypass graft surgery. J Stroke Cerebrovasc Dis. 2013;22:1304–11.

    Article  PubMed  Google Scholar 

  17. Martinelli J, Jiminez A, Rabago G, Artiz V, Fraile J, Farre J. Mechanical cardiac valve thrombosis: is thrombectomy justified? Circulation. 1991;84(5 Suppl):III70S–5.

    Google Scholar 

  18. Longstreth WT Jr, Bernick C, Fitzpatrick A, et al. Frequency and predictors of stroke death in 5888 participants in the Cardiovascular Health Study. Neurology. 2001;56(3):368–75.

    Article  PubMed  Google Scholar 

  19. Linkins LA, Choi PT, Douketis JD. Clinical impact of bleeding in patients taking oral anticoagulant therapy for venous thromboembolism: a metaanalysis. Ann Intern Med. 2003;139(11):893–900.

    Article  PubMed  Google Scholar 

  20. Husted S, van Giezen JJJ. Ticagrelor: the first reversibly binding oral P2Y12 receptor antagonist. Cardiovasc Ther. 2009;27(4):259–74.

    Article  CAS  PubMed  Google Scholar 

  21. Angiolillo DJ, Bhatt DL, Gurbel PA, Jennings LK. Advances in antiplatelet therapy: agents in clinical development. Am J Cardiol. 2009;103(Suppl 3):40A–51.

    Article  CAS  PubMed  Google Scholar 

  22. Safian RD. Bridging antiplatelet therapy prior to surgery in DES patients: is less more? Catheter Cardiovasc Interv. 2015;85:32–3.

    Article  PubMed  Google Scholar 

  23. Grines CL, Bonow RO, Casey DE Jr, et al. Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents: a science advisory from the American Heart Association, American College of Cardiology, Society for Cardiovascular Angiography and Interventions, American College of Surgeons, and American Dental Association, with representation from the American College of Physicians. Circulation. 2007;115(6):813–8.

    Article  PubMed  Google Scholar 

  24. Angiolillo DJ, Firstenberg MS, Price MJ, et al. Bridging antiplatelet therapy with cangrelor in patients undergoing cardiac surgery. A randomized controlled trial. JAMA. 2012;307(3):265–74.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Warshauer J, Patel VG, Christopoulos G, et al. Outcomes of preoperative bridging therapy for patients undergoing surgery after coronary stent implantation: a weighted meta-analysis of 280 patients from 8 studies. Catheter Cardiovasc Interv. 2015;85:25–31.

    Article  PubMed  Google Scholar 

  26. Thiele T, Sumnig A, Hron G, et al. Platelet transfusion for reversal of dual antiplatelet therapy in patients requiring urgent surgery: a pilot study. J Thromb Haemost. 2012;10(5):968–71.

    Article  CAS  PubMed  Google Scholar 

  27. Godier A, Taylor G, Gaussem P. Inefficacy of platelet transfusion to reverse ticagrelor. NEJM. 2015;372:196–7.

    Article  PubMed  Google Scholar 

  28. Freeman ML, Nelson DB, Sherman S, et al. Complications of endoscopic biliary sphincterotomy. N Engl J Med. 1996;335:909–18.

    Article  CAS  PubMed  Google Scholar 

  29. Baron TH, Kamath PS, Mcbane RD. Management of antithrombotic therapy in patients undergoing invasive procedures. N Engl J Med. 2013;368:2113–24.

    Article  CAS  PubMed  Google Scholar 

  30. Krishnamoorthy A, Sherwood MW, Lopes RD, Becker RC. The periprocedural management of novel oral anticoagulants in patients with nonvalvular atrial fibrillation: rationale and a summary of the available evidence from phase 3 clinical trials. Am Heart J. 2015;169:315–22.

    Article  CAS  PubMed  Google Scholar 

  31. Giugliano RP, Ruff CT, Braunwald E, et al. Edoxaban vs. warfarin in patients with atrial fibrillation. N Engl J Med. 2013;369:2093–104.

    Article  CAS  PubMed  Google Scholar 

  32. Arachchillage DRJ, et al. Efficacy and safety of prothrombin complex concentrate in patients treated with rivaroxaban or apixaban compared to warfarin presenting with major bleeding. Br J Haematol. 2019;184(5):808–16.

    Article  CAS  PubMed  Google Scholar 

  33. Schulman S, Carrier M, Lee AY, Shivakumar S, Blostein M, Spencer FA, Douketis JD. Perioperative Management of Dabigatran. Circulation. 2015;132(3):167–73.

    Article  CAS  PubMed  Google Scholar 

  34. Douketis J, Spyropoulos AC, Duncan JM, et al. Perioperative anticoagulant use for surgery evaluation (PAUSE) study: a perioperative management plan for patients with atrial fibrillation who are receiving a direct oral anticoagulant. Thromb Haemost. 2017;117(12):2415–24.

    Article  PubMed  Google Scholar 

  35. Landenhed M, Johansson M, Erlinge D, Olsson ML, Bjursten H. Fondaparinux or enoxaparin: a comparative study of postoperative bleeding in coronary artery bypass grafting surgery. Scand Cardiovasc J. 2010;44:100–6.

    Article  CAS  PubMed  Google Scholar 

  36. Sarode R. How do I transfuse platelets (PLTs) to reverse anti-PLT drug effect? Transfusion. 2012;52:695.

    Article  CAS  PubMed  Google Scholar 

  37. Pandit TN, Sarode R. Blood component support in acquired coagulopathic conditions: is there a method to the madness? Am J Hematol. 2012;87(Suppl 1):S56.

    Article  PubMed  Google Scholar 

  38. Thorne S, et al. The effect of platelet transfusion in patients with traumatic brain injury and concomitant antiplatelet use: a systematic review and meta-analysis. Transfusion. 2019;59:3536–44.

    Article  Google Scholar 

  39. Gratz I, Koehler J, Olsen D, et al. The effect of desmopressin acetate on postoperative hemorrhage in patients receiving aspirin therapy before coronary artery bypass operations. J Thorac Cardiovasc Surg. 1992;104:1417–22.

    Article  CAS  PubMed  Google Scholar 

  40. Beshay JE, Morgan H, Madden C, et al. Emergency reversal of anticoagulation and antiplatelet therapies in neurosurgical patients. J Neurosurg. 2010;112:307–18.

    Article  CAS  PubMed  Google Scholar 

  41. Bhatt DL, et al. Antibody-based Ticagrelor reversal agent in healthy volunteers. N Engl J Med. 2019;380:1825–33.

    Article  CAS  PubMed  Google Scholar 

  42. Bauer KA. Targeted anti-anticoagulants. N Engl J Med. 2015;373:569–71.

    Article  CAS  PubMed  Google Scholar 

  43. Ansell JE, Bakhru SH, Laulicht BE, Steiner SS, Grosso M, Brown K, Dishy V, Noveck RJ, Costin JC. Use of PER977 to reverse the anticoagulant effect of edoxaban. N Engl J Med. 2014;371:2141–2.

    Article  PubMed  Google Scholar 

  44. Sarode R, Milling TJ Jr, Refaai MA, et al. Efficacy and safety of a 4-factor prothrombin complex concentrate in patients on vitamin K antagonists presenting with major bleeding: a randomized, plasma-controlled, phase IIIb study. Circulation. 2013;128:1234–43.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  45. Goldstein JN, et al. Four-factor prothrombin complex concentrate versus plasma for rapid vitamin K antagonist reversal in patients needing urgent surgical or invasive interventions: a phase 3b, open-label, non-inferiority, randomised trial. Lancet. 2015;385(9982):2077–87.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  46. Chai-Adisaksopha C, Crowther M, Isayama T, Lim W. The impact of bleeding complications in patients receiving target specific oral anticoagulants: a systematic review and meta-analysis. Blood. 2014;124:2450–8.

    Article  CAS  PubMed  Google Scholar 

  47. Pollack CV Jr, Reilly PA, Eikelboom J, Glund S, Verhamme P, Bernstein RA, Dubiel R, Huisman MV, Hylek EM, Kamphuisen PW, Kreuzer J, Levy JH, Sellke FW, Stangier J, Steiner T, Wang B, Kam CW, Weitz JI. Idarucizumab for dabigatran reversal. N Engl J Med. 2015;373(6):511.

    Article  CAS  PubMed  Google Scholar 

  48. Connolly SJ, et al. Full study report of Andexanet Alfa for bleeding associated with factor Xa inhibitors. N Engl J Med. 2019;380(14):1326–35.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  49. Pollack CV, Reilly PA, van Ryn J. Idarucizumab for Dabigatran reversal – full cohort analysis. NEJM. 2017;377(5):431–41.

    Article  CAS  PubMed  Google Scholar 

  50. Siegal DM, Curnutte JT, Connolly SJ, et al. Andexanet alfa for the reversal of factor Xa inhibitor activity. N Engl J Med. 2015;373:2413–24.

    Article  CAS  PubMed  Google Scholar 

  51. Shah SB, Pahade A, Chawla R. Novel reversal agents and laboratory evaluation for direct-acting oral anticoagulants (DOAC): an update. Indian J Anaesth. 2019;63:169–81.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  52. Levy JH, et al. When and how to use antidotes for the reversal of direct oral anticoagulants: guidance from the SSC of the ISTH. J Thromb Haemost. 2016;14(3):623–7.

    Article  CAS  PubMed  Google Scholar 

  53. Albaladejo P, Bonhomme F, Blais N, Collet JP, Faraoni D, Fontana P, Godier A, Llau J, Longrois D, Marret E, et al. Management of direct oral anticoagulants in patients undergoing elective surgeries and invasive procedures: updated guidelines from the French Working group on Perioperative Hemostasis (GIHP) - September 2015. Anaesth Crit Care Pain Med. 2017;36(1):73–6.

    Article  PubMed  Google Scholar 

  54. Leitch J, van Vlymen J. Can J Anesth/J Can Anesth. 2017;64:656.

    Article  Google Scholar 

  55. Maddali S, Biring T, Bluhm J, Kopecky S, Krueger K, Larson T, et al. Antithrombotic therapy supplement [Internet]. Bloomington: Institute for Clinical Systems Improvement (ICSI); 2013.

    Google Scholar 

  56. Lu G, et al. A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa. Nat Med. 2013;19(4):446–53.

    Article  CAS  PubMed  Google Scholar 

  57. Levy J, Spyropoulos A, Samama C, Douketis J. Direct oral anticoagulants: new drugs and new concepts. J Am Coll Cardiol Intv. 2014;7:1333–51.

    Article  CAS  Google Scholar 

  58. Ansell JE, Bakhru SH, Laulicht BE, et al. Use of PER977 to reverse the anticoagulant effect of edoxaban. N Engl J Med. 2014;371:2141–2.

    Article  PubMed  Google Scholar 

  59. Bhat V, Gale AJ, Griffin JH, et al. Reversal of novel oral anticoagulant (DOAC)-induced bleeding in mice by engineered superfactor Va. Blood. 2014;124:695.

    Article  Google Scholar 

  60. Thalji NK, Ivanciu L, Jasuja R, et al. Zymogen-like FXa is a potent bypassing agent for reversal of direct FXa inhibitors in vivo. Blood. 2014;124:582.

    Article  Google Scholar 

  61. Garcia DA. Parenteral anticoagulants. Chest. 2012;141(2 Suppl):e24S–3.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  62. Ortel TL. Perioperative management of patients on chronic antithrombotic therapy. Blood. 2012;120:4699–705.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  63. Yates SW. Interrupting anticoagulation in patients with nonvalvular atrial fibrillation. PT. 2014;39(12):858–80.

    Google Scholar 

  64. Patrono C, Baigent C, Hirsh J, Roth G. Antiplatelet drugs: American College of chest physicians evidence-based clinical practice guidelines (8th ed.). Chest. 2008;133(Suppl 6):199S–233.

    Article  CAS  PubMed  Google Scholar 

  65. Li C, Hirsh J, Xie C, Johnston MA, Eikelboom JW. Reversal of the anti-platelet effects of aspirin and clopidogrel. J Thromb Haemost. 2012;10(4):521–8.

    Article  CAS  PubMed  Google Scholar 

  66. Pletal (cilostazol) (prescribing information). Rockville: Otsuka America Pharmaceutical Inc.; 2015.

    Google Scholar 

  67. Ferraris VA, Saha SP, Oestreich JH, et al. 2012 update to the Society of Thoracic Surgeons guideline on use of antiplatelet drugs in patients having cardiac and noncardiac operations. Ann Thorac Surg. 2012;94(5):1761–81.

    Article  PubMed  Google Scholar 

  68. Heidbuchel H, Verhamme P, Alings M, et al. EHRA practical guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation: executive summary. Eur Heart J. 2013;34(27):2094–106.

    Article  CAS  PubMed  Google Scholar 

  69. Siegal DM. Hematology Am Soc Hematol Educ Program. 2019;2019(1):198–203.

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Internal Medicine, Division of Hematology and Oncology, University of Texas Southwestern, Dallas, TX, USA

    Ibrahim F. Ibrahim

  2. Department of Medicine, Weill Cornell Medical College (Houston campus), Houston, TX, USA

    Lawrence Rice

  3. Department of Medicine and Cancer Center, Houston Methodist Hospital, Houston, TX, USA

    Lawrence Rice

Authors
  1. Ibrahim F. Ibrahim
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Lawrence Rice
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ibrahim F. Ibrahim .

Editor information

Editors and Affiliations

  1. Department of Pathology and Immunology, Division of Transfusion Medicine and Coagulation, Baylor College of Medicine, Texas Children’s Hospital, Houston, TX, USA

    Jun Teruya

Rights and permissions

Reprints and permissions

Copyright information

© 2021 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Ibrahim, I.F., Rice, L. (2021). Antiplatelet and Anticoagulant Agents. In: Teruya, J. (eds) Management of Bleeding Patients. Springer, Cham. https://doi.org/10.1007/978-3-030-56338-7_30

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-56338-7_30

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-56337-0

  • Online ISBN: 978-3-030-56338-7

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation